![Bill Begien](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Bill Begien is Vice President-Investor Relations at NovaBridge Biosciences.
Mr. Begien is Senior Vice President-Investor Relations at CDT Equity, Inc. Mr. Begien was Vice President-Investor Relations at TFF Pharmaceuticals, Inc. from 2022 to 2023.
Postes actifs de Bill Begien
| Sociétés | Poste | Début |
|---|---|---|
| CDT EQUITY INC. | Investor Relations Contact | 01/09/2023 |
| NOVABRIDGE BIOSCIENCES | Investor Relations Contact | - |
Anciens postes connus de Bill Begien
| Sociétés | Poste | Fin |
|---|---|---|
| TFF PHARMACEUTICALS, INC. | Investor Relations Contact | 01/10/2023 |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
4
Relations au 1er degré
3
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
TFF Pharmaceuticals, Inc.
 TFF Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures inhaled dry powder drugs for the treatment of pulmonary diseases and conditions | Health Technology |
I-Mab
 I-Mab Pharmaceuticals: MajorHealth Technology Develops and manufactures medicines for cancer and autoimmune diseases | Health Technology |
Conduit Pharmaceuticals, Inc.
 Conduit Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage specialty biopharmaceutical company | Health Technology |
